These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Benzinga

2025/07/30

Dyne Therapeutics Inc (NASDAQ:DYN) reported a loss for the second quarter on Monday.

The company posted a quarterly loss of 97 cents per share, which met the analyst consensus estimate.

“This quarter we made significant progress on our clinical and regulatory plans for our DM1 and DMD investigational therapies, as we advance both programs toward potential U.S. Accelerated Approval submissions in 2026 and possible commercial launches in 2027,” said John Cox, president and chief executive officer of Dyne. “We also strengthened our balance sheet, extending our cash runway into the third quarter of 2027 and believe we are well funded to achieve multiple value-creating milestones including two data readouts in DM1 and DMD, two potential U.S. Accelerated Approval submissions in those indications, and the potential launch of DYNE-251 in DMD in the U.S.”

Dyne Therapeutics shares fell 2.5% to trade at $9.08 on Tuesday.

These analysts made changes to their price targets on Dyne Therapeutics following earnings announcement.

Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.
Raymond James analyst Martin Auster reiterated the stock with an Outperform rating and lowered the price target from $37 to $31.
RBC Capital analyst Luca Issi maintained Dyne Therapeutics with an Outperform rating and cut the price target from $25 to $23.

Considering buying DYN stock? Here’s what analysts think:

Read This Next:

Uber To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555063595"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555063595\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555063595?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555063595","market":"us","top_or_hot":-1,"title":"These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss","media":"Benzinga","content":"<html><body><p><strong>Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc</strong> (NASDAQ:DYN) reported a loss for the second quarter on Monday.</p>\n<p>The company posted a quarterly loss of 97 cents per share, which met the analyst consensus estimate.</p>\n<p>“This quarter we made significant progress on our clinical and regulatory plans for our DM1 and DMD investigational therapies, as we advance both programs toward potential U.S. Accelerated Approval submissions in 2026 and possible commercial launches in 2027,” said John Cox, president and chief executive officer of Dyne. “We also strengthened our balance sheet, extending our cash runway into the third quarter of 2027 and believe we are well funded to achieve multiple value-creating milestones including two data readouts in DM1 and DMD, two potential U.S. Accelerated Approval submissions in those indications, and the potential launch of DYNE-251 in DMD in the U.S.”</p>\n<p>Dyne Therapeutics shares fell 2.5% to trade at $9.08 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Dyne Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.</li>\n<li><a href=\"https://laohu8.com/S/RJF\">Raymond James</a> analyst Martin Auster reiterated the stock with an Outperform rating and lowered the price target from $37 to $31.</li>\n<li>RBC Capital analyst Luca Issi maintained Dyne Therapeutics with an Outperform rating and cut the price target from $25 to $23.</li>\n</ul>\n<p><strong>Considering buying DYN stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"591\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-1024x591.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462.png 1126w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong><a href=\"https://laohu8.com/S/UBER\">Uber</a> To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-07-30 00:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc</strong> (NASDAQ:DYN) reported a loss for the second quarter on Monday.</p>\n<p>The company posted a quarterly loss of 97 cents per share, which met the analyst consensus estimate.</p>\n<p>“This quarter we made significant progress on our clinical and regulatory plans for our DM1 and DMD investigational therapies, as we advance both programs toward potential U.S. Accelerated Approval submissions in 2026 and possible commercial launches in 2027,” said John Cox, president and chief executive officer of Dyne. “We also strengthened our balance sheet, extending our cash runway into the third quarter of 2027 and believe we are well funded to achieve multiple value-creating milestones including two data readouts in DM1 and DMD, two potential U.S. Accelerated Approval submissions in those indications, and the potential launch of DYNE-251 in DMD in the U.S.”</p>\n<p>Dyne Therapeutics shares fell 2.5% to trade at $9.08 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Dyne Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.</li>\n<li><a href=\"https://laohu8.com/S/RJF\">Raymond James</a> analyst Martin Auster reiterated the stock with an Outperform rating and lowered the price target from $37 to $31.</li>\n<li>RBC Capital analyst Luca Issi maintained Dyne Therapeutics with an Outperform rating and cut the price target from $25 to $23.</li>\n</ul>\n<p><strong>Considering buying DYN stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"591\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-1024x591.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29124949/image-462.png 1126w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong><a href=\"https://laohu8.com/S/UBER\">Uber</a> To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday</strong></li>\n</ul>\n<p>Photo via <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46697991/these-analysts-lower-their-forecasts-on-dyne-therapeutics-following-q2-loss","article_id":"2555063595","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555063595","pubTimestamp":1753807898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LENZ":"Therapeutics","BK4585":"ETF&股票定投概念","BK4539":"次新股","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4007":"制药","DYN":"戴纳基"},"translate_title":"这些分析师在第二季度亏损后下调了对Dyne Therapeutics的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":1,"LENZ":1},"content_text":"Dyne Therapeutics Inc (NASDAQ:DYN) reported a loss for the second quarter on Monday.\nThe company posted a quarterly loss of 97 cents per share, which met the analyst consensus estimate.\n「This quarter we made significant progress on our clinical and regulatory plans for our DM1 and DMD investigational therapies, as we advance both programs toward potential U.S. Accelerated Approval submissions in 2026 and possible commercial launches in 2027,」 said John Cox, president and chief executive officer of Dyne. 「We also strengthened our balance sheet, extending our cash runway into the third quarter of 2027 and believe we are well funded to achieve multiple value-creating milestones including two data readouts in DM1 and DMD, two potential U.S. Accelerated Approval submissions in those indications, and the potential launch of DYNE-251 in DMD in the U.S.」\nDyne Therapeutics shares fell 2.5% to trade at $9.08 on Tuesday.\nThese analysts made changes to their price targets on Dyne Therapeutics following earnings announcement.\n\nChardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.\nRaymond James analyst Martin Auster reiterated the stock with an Outperform rating and lowered the price target from $37 to $31.\nRBC Capital analyst Luca Issi maintained Dyne Therapeutics with an Outperform rating and cut the price target from $25 to $23.\n\nConsidering buying DYN stock? Here’s what analysts think: \n\nRead This Next: \n\nUber To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}